Progressive Supranuclear Palsy

Typical clinical presentation -Richardson syndrome
Progressive supranuclear palsy is the second most common form of parkinsonism after idiopathic Parkinson disease 8 . This neurodegenerative condition was first described in 1964 by Steele, Richardson and Olszewski as an "unusual syndrome" characterized by a combination of progressive postural instability with axial rigidity, supranuclear gaze palsy, mild dementia and pseudobulbar palsy 9 , without tremor or limb bradykinesia and rigidity 10 . Since the first description almost 50 years ago, many more case reports lead to a better description of the clinical presentation. The most important clinical features for diagnosis of PSP, as stated in the NINDS-SPSP diagnostic criteria, are the presence of early and prominent postural instability leading to falls and supranuclear gaze palsy (SNGP), along with a progressive course 11 . As SNGP with difficulty looking either up or down generally develops years after disease onset, this is not useful for early diagnosis, although impairment of vertical and horizontal saccades and presence of square wave jerks can be early diagnostic clues [12] [13] [14] . Patients with PSP typically exhibit axial rigidity, slurred speech, swallowing difficulties, eyelid retraction with staring gaze, sometimes associated with dystonic retrocollis, blepharospasm or eyelid opening apraxia 10, 15 . Many recent reports have shown that not only dysarthria, but also non fluent aphasia and apraxia of speech were common in PSP 16 . Neuropsychiatric symptoms develop in more than half the patients within two years of disease onset 17 and include subcortical dementia with prominent cognitive slowing, poor recall, attention and frontal executive deficits, along with personality changes such as apathy, irritability and disinhibition, a profile mimicking bifrontal lobe disease [17] [18] [19] [20] . Following symptom onset, patients with PSP experience a relentless progression with death within five to eight years 10 .
Atypical clinical presentations
Following the early descriptions of typical Richardson syndrome, there have been a number of cases reported with pathological findings of PSP but atypical clinical presentations, suggesting there is a great clinical variability among patients with PSP pathology. Although SNGP was considered in the NINDS-SPSP criteria to be a mandatory finding for a clinical diagnosis of PSP 11 , we now know that many patients with this condition never develop eye movement abnormalities 14, [21] [22] [23] [24] . Some individuals present with asymmetric rigidity, tremor and a moderate response to levodopa mimicking idiopathic Parkinson disease (PD) 10, 25 or with asymmetrical cortical symptoms mimicking CBD, such as apraxia, alien limb, arm levitation or hemidystonia 21, [26] [27] [28] [29] [30] [31] . Cognitive decline and behavioural changes are the presenting complaint in 15% to 30% of cases 17, 25, 32 and can remain the only clinical feature throughout the disease 23, [33] [34] [35] speech or progressive non fluent aphasia 16, [34] [35] [36] [37] [38] [39] [40] . Some of these cases later developed mild parkinsonism, apraxia or eye movement abnormalities, but others had an isolated speech disturbance until death [34] [35] [36] . Williams et al 10 have recently suggested a new classification to account for the different clinical presentations of pathologically proven PSP. They have described five distinct presentations of PSP: Richardson syndrome (the classic clinical picture of PSP), PSP-parkinsonism (asymmetrical onset of limb rigidity and bradykinesia with or without tremor and levodopa response), pure akinesia with freezing of gait, PSP presenting as a corticobasal syndrome and PSP presenting as apraxia of speech or progressive non fluent aphasia ( Table 2) .
The clinical heterogeneity of PSP leads to common diagnostic errors. Clinicopathologic studies have shown that only 35% to 64% of patients with PSP pathology at autopsy had an accurate clinical diagnosis during life 21, 24, 34, 35 . Alternate clinical diagnosis include CBD, PD, primary progressive aphasia, FTLD, AD and cerebrovascular disease 21, 24, 34, 35 .
Other conditions mimicking the PSP syndrome
A number of neurodegenerative conditions can mimick the symptoms of PSP, leading to clinical misdiagnosis. Among patients with a PSP-like clinical picture, only 62% to 91% do have PSP pathology at autopsy 35, [41] [42] [43] . The disorders most commonly mistaken for PSP during life are CBD, PD with concomitant AD or lewy body pathology, multiple system atrophy, AD and FTLD 29, 35, [41] [42] [43] [44] . 
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Typical pathology of PSP
Macroscopically, the pathological findings of PSP include predominant midbrain atrophy, some degree of atrophy of the pallidum, thalamus, and subthalamic nucleus and mild symmetric frontal atrophy 9, 45 . Histopathology is characterized by accumulation in the brain of abnormal 4R-tau protein within neurons (globose and flame-shaped neurofibrillary tangles and neuropil threads) and glial cells (tufted astrocytes, thorn-shaped astrocytes and coiled bodies) 34, 46, 47 . The distribution of tau inclusions is mainly subcortical in the globus pallidus, subthalamic nucleus, substantia nigra and brainstem, which are severely affected in most cases 34, 46, 48 . Tau pathology also occurs to a lesser extent in the dentate nucleus of the cerebellum 46, 48 . Cortical involvement is a common finding in PSP although not considered so initially 10 ; motor and premotor cortices typically show abundant tufted astrocytes whereas some neurofibrillary tangles or pre-tangles can be found in the hippocampus and frontal or insular cortices 15, 24, 46, 47 . The classic Richardson syndrome is the most commonly associated with such typical PSP pathology 10 .
Atypical pathology of PSP
Atypical pathological cases of PSP are variants in which the severity or distribution of abnormalities deviate from the typical pattern 46 . For example, some cases of PSP have been described with severe neocortical involvement in addition to typical or milder subcortical pathology; these patients tend to present with asymmetrical cortical symptoms such as apraxia, alien limb phenomenon or progressive aphasia, with or without the expected symptoms of PSP 24, 36, [49] [50] [51] [52] [53] . Other patients tend to have a more restricted pattern of distribution of tau pathology with less involvement of the motor cortex, striatum, pontine nuclei and cerebellum; such individuals usually present with prominent gait instability without dementia or SNGP 10, 54, 55 . Another variant has been described where tau burden is less severe although with a similar distribution as in Richardson syndrome, leading to a slower disease progression and a clinical picture resembling PD 10, 54, 56 . Therefore, it appears that the severity and distribution of tau pathology in PSP are responsible for the variability in clinical presentation.
Corticobasal Degeneration
Typical clinical presentation -The corticobasal syndrome
The first report of three patients who developed a syndrome called "corticodentatonigral degeneration with neuronal achromasia" characterized by progressive asymmetric slowness and awkwardness of voluntary movements with superimposed involuntary movements and late cognitive dysfunction was published in 1967 57 . Twenty years later, the name "corticobasal degeneration" was introduced by Gibb et al to describe the same disorder 58 . The clinical hallmark of CBD is a combination of progressive cortical and extrapyramidal dysfunction, the latter being unilateral at onset and remaining very asymmetrical until death (also called "corticobasal syndrome" (CBS)). Basal ganglia involvement manifests as asymmetric akinesia, rigidity, dystonia, myoclonus, tremor or any combination of the above; cortical features include alien limb phenomenon, ideomotor apraxia, cortical sensory loss or aphasia [58] [59] [60] . Patients with CBD do not have a dramatic response to levodopa therapy.
For many years, dementia was considered an atypical finding in patients with CBD 61 , but more recent studies have shown that dementia is present in 35-70% of patients at onset 59, 62 and eventually develops in everyone 63 . Cognitive dysfunction is of the "frontal" type with impairment in executive functions, setshifting tasks, attention and visuospatial tasks 20, 64, 65 . Depression, apathy, irritability, disinhibition and other personality changes similar to those found in the behavioral variant of frontotemporal dementia are also common 20, 63, 66 . Speech and language complaints are frequently noted at onset and eventually develop in 90-94% of patients later in the disease 59, 67, 68 . Speech disturbances manifest as progressive non fluent aphasia, apraxia of speech, dysarthria, dysphonia or sometimes mutism 16, 20, 59, 67, 68 . Over time, most patients develop oculomotor apraxia and postural instability 59 .
Atypical clinical presentations
Apart from the classical syndrome, patients with pathologically-proven CBD can present with a variety of different clinical pictures. Clinical misdiagnosis occurs in 47-69% of patients 35, 59, 69 and is associated with the lack of expected features (apraxia, alien limb, dystonia, parkinsonism) or the presence of unexpected findings (early prominent gait disorder or supranuclear gaze palsy). Common erroneous diagnosis include PSP, FTLD, AD, progressive non fluent aphasia, PD or Lewy body dementia (LBD) 35, 59, 69, 70 .
The early clinical presentation of CBD can be either motor or neuropsychiatric 63 . Some patients present with prominent gait disorder, falls and eye movement abnormalities suggesting a diagnosis of PSP 29, 35, 44, 58, 60 . However, the majority of patients with pathologically-proven CBD do not present with a movement disorder but rather with isolated cognitive, behavioral or language changes 20, 60, 69 . Cognitive and personality changes typically suggest frontal dysfunction similar to that seen in FTLD, but some cases exhibit a posterior cortical atrophy syndrome (Balint or Gerstmann syndromes, visual agnosia, agraphia, alexia) 71, 72 . Progressive aphasia or apraxia of speech are particularly common presenting features 16, [73] [74] [75] [76] and were the presenting symptom in 25% of the cases reviewed by Wadia and Lang 60 . Most patients who present initially without extrapyramidal features develop them over time, either early or late in the disease process. Some cases never exhibit clinically significant basal ganglia dysfunction 20, 35, 69, 76, 77 and are therefore misdiagnosed as having some form of dementia.
Other conditions mimicking the corticobasal syndrome
The typical syndrome characterized by a combination of unilateral movement disorder and cortical features was initially thought to be exclusive to CBD, but clinicopathological studies have shown that only about half of cases with clinical CBS have CBD pathology 31, 35, 68 . Other conditions reported as causing CBS include PSP, AD, Pick disease, tau-negative FTLD, FTDP-17, Creutzfeldt-Jakob disease and LBD 31, 60 . Given such pathological heterogeneity, CBS should not be considered a hallmark of CBD.
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Typical pathology of CBD
Macroscopically, CBD pathology is characterized by asymmetric fronto-parietal cortical atrophy, most severe in the peri-Rolandic distribution 49 . Histological changes include neuronal loss in the affected cortical areas, substantia nigra, globus pallidus and neostriatum along with spongiosis of the cortical neuropil 49, 78 . Tau-positive inclusions (4R isoform) are found in the neurons and glia of both gray and white matter. Intraneuronal inclusions in the substantia nigra and subcortical nuclei resemble the globose neurofibrillary tangles seen in PSP, whereas cortical neuronal inclusions can be diffuse, granular, crescent-shaped or globular, sometimes reminiscent of Pick bodies 49, 78 . Oligodendroglial inclusions ("coiled body") are widely distributed, along with tau-positive neuropil threads 78 . The most characteristic lesion seen in CBD is the astrocytic plaque found in affected cerebral cortices 49 ; it is considered the pathological hallmark of the disease. Cortical ballooned neurons resembling Pick's cells are also an important histologic feature 49 . In CBD, there are no tufted astrocytes, which are considered typical of PSP.
Atypical pathology of CBD
As described above, the majority of patients with CBD pathology have predominant involvement of frontoparietal cortices, especially around the central sulcus, associated with some subcortical changes. However, atypical distributions of pathological lesions suggestive of CBD have been reported and can be divided in three subtypes: predominant anterior frontal, superior temporal or subcortical pathology. Some cases have been described where the focus of degeneration was shifted from the central region to the anterior frontal cortex 49 . Interestingly, these patients presented clinically with personality changes, behavioural changes or cognitive decline and not with extrapyramidal features 51, 79, 80 . Another subgroup of patients presenting with progressive aphasia exhibit severe involvement of the superior temporal gyrus or Broca's area 51, 80 . The term "minimal change CBD" has been used to describe cases of CBD with only minimal cortical pathology and heavier subcortical lesions. Once again, patients with this atypical distribution of lesions do not present with CBS but rather with symmetric parkinsonism poorly responsive to levo-dopa and prominent gait disturbance, sometimes associated with SNGP and dementia 49, 51, [80] [81] [82] [83] [84] . Therefore, it appears that atypical clinical presentations of CBD are related to unusual distribution of CBD pathological lesions.
Frontotemporal lobar degeneration
Clinical elements
The clinical diagnosis of FTLD refers to a spectrum of clinical syndromes characterized by progressive behavioral changes and language deficits. In 1998, a consensus conference divided the FTLD group into three clinical presentations, now referred to as the behavioral variant of frontotemporal dementia (bv-FTD), progressive non fluent aphasia (PNFA) and semantic dementia (SD) 85 . These three syndromes have overlapping features, typically sharing a combination of behaviour and personality changes, executive dysfuntion and language impairment. However, each variant is characterized by the predominant feature. Hence, bv-FTD is diagnosed when cognitive decline and personality changes overshadow the language deficit, and a diagnosis of PNFA or SD is made when language impairment is the predominant symptom 7 . Extrapyramidal features develop in about 30% of patients during the course of the disease, according to Kertesz and Munoz 66 , mostly with the PNFA variant.
Behavioral variant of frontotemporal dementia
Behavioral variant of frontotemporal dementia is characterized by insidious onset and gradual progression of prominent behavior and personality changes associated with frontal executive deficits. Diagnostic criteria include decline in social conduct, poor hygiene, loss of insight, emotional blunting, mental rigidity, impersistence, hyperorality (such as sweet cravings), perseveration and stereotyped behavior 85 . Impulsivity, disinhibition, and apathy are also common. The cognitive profile is notable for executive deficits with relatively spared memory and visuospatial functions. Speech and language can be affected in a similar fashion to that seen in PNFA or SD, although it is not usually a major feature and can occur later. Over time, some patients will develop extrapyramidal elements, such as parkinsonism or CBS 37, 38, 69, [86] [87] [88] .
Progressive Non-Fluent Aphasia
Effortful, non fluent speech with agrammatism is the hallmark of PNFA. Such a language disorder is often associated with apraxia of speech, which is not a language but a speech disorder, characterized by slow speech, abnormal prosody, decreased articulatory accuracy and distorted sound substitutions, additions or repetitions 16 . Similarly to the other FTLD variants, the symptoms of PNFA are insidious and slowly progressive. Although behavioral and personality changes can occur (at onset or up to many years later), such features are not as common as seen in bv-FTD and SD 7 .
Later developement of extrapyramidal features, however, is particularly frequent in cases presenting with PNFA and/or apraxia of speech. Corticobasal syndrome is by far the most common motor syndrome associated with primary progressive aphasia, occuring in 40% of patients in one study 37 . Mild parkinsonism or a PSP-like picture have also been reported 16 .
Semantic Dementia
Semantic dementia is characterized by loss of verbal semantic knowledge, impaired comprehension and semantic paraphasias. This entity will not be discussed in detail in this review as it is rarely associated with tau-positive inclusions and has little overlap with CBD and PSP.
Pathology and clinicopathological correlation
Frontotemporal lobar degeneration is a clinical diagnosis associated with heterogeneous pathological entities, which can be divided into tau-positive or tau-negative. The Work Group on Frontotemporal Dementia and Pick's Disease further classified FTLD into five neuropathological categories (Table 3) 89 . Although half the cases of clinical FTLD are tau-negative 70, 90 , it is evident from this classification that CBD and PSP are also possible aetiologies for this clinical presentation. One study
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found CBD pathology to be particularly common, accounting for 20% of their patients with FTLD presentation 90 .
Histopathology is difficult to predict in patients with clinical bv-FTD. The majority are found to have tau-negative pathologies such as DLDH, TDP-43 proteinopathy or AD. However, 40-50% of cases will have a tauopathy, most commonly Pick disease but also CBD and PSP 35, 37, 70 . One of the observed trends is that presence of extrapyramidal features at any stage during the disease process more likely predicts taupositive inclusions 37, 63, 70, 90 .
As opposed to bv-FTD, primary progressive aphasia is highly predictive of an underlying tauopathy, found in about 80% of cases in most studies 35, 70, 91 . Corticobasal degeneration pathology is more likely when parkinsonism or apraxia is present 63, 70 , although many patients never develop such features. Progressive non fluent aphasia has been associated strongly both with Pick's disease 70 and CBD 37, 91 , whereas PSP typically underlies early and prominent apraxia of speech 36, 91 .
Given the strong clinical and pathological overlap between tau-positive bv-FTD, PNFA, CBD and PSP, some authors argue they should all be considered as subtypes of Pick disease, and the term "Pick complex" was suggested to encompass those disorders 35, 92 .
Frontotemporal dementia with parkinsonism linked to chromosome 17
Frontotemporal dementia with parkinsonism linked to chromosome 17 is a term used for a heterogeneous group of disorders sharing similar clinical, pathological and genetic features. The clinical phenotype is dominated by dementia of the frontal type or Alzheimer type, associated with variable parkinsonism ranging from a non dopa-responsive parkinsonism (without or without tremor), to a CBS or PSP-like syndrome 45, [93] [94] [95] [96] [97] [98] [99] [100] [101] . Therefore, FTDP-17 is often misdiagnosed as FTLD, PSP or CBD. Histopathology can resemble that of PSP, CBD or even Pick's disease 101, 102 . All cases of FTDP-17 are caused by a mutation in the gene that encodes microtubule-associated tau (MAPT) on chromosome 17. Most are transmitted in an autosomal dominant fashion, but autosomal recessive transmission has also been described 99 . Many different mutations have been reported, including missense mutations affecting one of the exons (exon 9, exon 10, exon 12, or exon 13), silent mutations affecting exon 10, and substitutions in the intron following exon 10 or more rarely exon 9 78 . All mutations result in formation of hyperphosphorylated tau filaments, which composition (3R or 4R) depends on the type of mutation; mutations in exon 10 or intron 10 will result in 4R-tau accumulation 7, 78, 94, 97 .
Are PSP, CBD and FTLD part of the same disease spectrum?
Clinical and pathological overlap PSP, CBD, PNFA and some cases of bv-FTD and FTDP-17 have overlapping clinical and pathological features. The margins among the clinical presentations of these disorders are blurring, as symptoms thought to be typical for a particular disease can also be found in another disease. For example, PNFA or behavioral and cognitive changes suggestive of bv-FTD are found in CBD or PSP, sometimes with little or absent parkinsonism, CBS can be a prominent feature in PSP or some forms of FTLD, and a PSP-like presentation can be caused by CBD pathology. The clinical overlap is so great that it becomes difficult to predict pathology from the clinical presentation, with a success rate as low as 50% for CBS and 60% for PSP 35, 43 .
Clinicopathological studies in case reports of patients with unexpected clinical presentations for a particular disorder often have microscopic findings that extend beyond the expected areas for this disorder. Severe cortical involvement or asymmetric cortical atrophy expected in CBD is unusual for PSP, but has been described in many cases, most of which exhibited focal cortical signs such as apraxia or aphasia 21, [26] [27] [28] [29] [30] [31] . On the other hand, several cases of CDB presenting with symmetric parkinsonism and prominent gait disturbance have been reported to show minimal cortical pathology 49 . Patients with prominent behavioral changes tend to have more severe pathology in the anterior frontal cortices, and those with progressive aphasia show a high burden of lesions in the dominant temporal lobe. Therefore, it appears the distribution of lesions explains the clinical presentation, and not the morphology of tau aggregates (astrocytic plaque, tufted astrocytes, etc.).
The pathological similarities between CBD and PSP extend beyond the simple topography of tau-inclusions. In both disorders, insoluble tau is predominantly of 4R-tau isoforms consisting biochemically of two major bands at 64 and 68 kDa and a variable minor band at 72 kDa 78, [103] [104] [105] . In both diseases, the tangles are ultrastructurally composed of characteristic 15nm-wide straight tubules 81, 106 . Also, a few studies have failed THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 552 3. 3R and 4R tau-positive inclusions (neurofibrillary tangle dementia, to reveal a clear difference in the tau epitopes displayed by the pathological accumulation of tau in PSP and CBD 107, 108 . Despite the identical composition of tau isoforms, Arai et al showed distinctive patterns of tau fragments on immunoblot analysis of sarkosyl-insoluble brain extracts of patients with CBD and PSP, suggesting that different proteolytic processing of abnormal tau takes place in these two diseases 109, 110 . Another important difference between tau aggregates in PSP and CBD is obviously their morphology: in PSP, the typical tau inclusions take the form of tufted astrocytes, whereas in CBD they form astrocytic plaques. The pathophysiological processes leading to such morphologies are not clear.
It is not known whether PSP and CBD come from distinct insults and pathophysiological processes or if they share some elements of pathophysiology that may evolve differently in different individuals, due to genetic or environmental factors. The latter hypothesis is supported by the report of a single family with histopathologically confirmed CBD in one sibling and PSP in another (both with clinical CBS), along with three more siblings fulfilling the criteria for clinically probable PSP 111 . However, genetic studies did not reveal a pathogenic tau mutation in this family 111 and therefore it is possible that combination of PSP and CBD be related to two different disease processes. Descriptions of combined occurrence of astrocytic plaques and tufted astrocytes in a same patient also suggest a shared pathophysiological pathway for PSP and CBD 34, [112] [113] [114] .
Genetics
Recent genetic discoveries also support the overlap between PSP, CBD and some forms of tau-positive FTLD. There have been many reports of mutations of the MAPT gene on chromosome 17 (FTDP-17) resulting in clinical or pathological phenotype suggesting either of these disorders [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] 115 . Moreover, the same mutation can result in one clinical syndrome in one family and another in a different family. There is even a report of an identical tau mutation in a family leading to clinical CBS in the son and FTLD in the father 95 . These evidences reinforce that an identical initial insult (in this case a tau mutation) can lead to distinct clinical and pathological features in the spectrum of PSP, CBD or FTLD in different individuals, suggesting there may be a different processing of the abnormal protein in different subjects which would account for these differences. These differences in the morphology and location of tau aggregates could be related to individual genetic polymorphisms or mutations in the tau gene or other related genes, or to environmental factors which are yet to be identified.
Progressive supranuclear palsy and corticobasal degeneration also share a similar genetic background. Case control studies have demonstrated a significant association between the H1 haplotype of the tau gene and both PSP and CBD 116, 117 . Conrad et al provided the first evidence of an association between the A0 allele of the tau gene and sporadic PSP 118 ; the A0 allele was later shown to segregate with a tau haplotype, designated H1 117 . In a normal caucasian population, homozygosy for the H1 haplotype (H1/H1) is found in 50-70% of the population, whereas the frequency of H1/H1 in both PSP and CBD is significantly higher (80-90%) compared with controls 115, 116, 119 . The exact mechanism by which the H1 haplotype confers an increased risk for these conditions is not known 111 . One study also reports an association between the A0 allele and FTLD 120 , whereas others do not support such an association 119, 121 .
No clinical syndrome is exclusive to tauopathies
Neurodegenerative diseases not involving tau aggregates but involving deposition of ubiquitin, alphasynuclein or other abnormal proteins can also lead to clinical syndromes suggestive of PNFA, bv-FTD, PSP or CBD. For example, progranulin mutation has been reported in 5-10% of FTLD 7 and can also cause CBS 60 . Mutations in presenilin, VCP, CHMP2B, TARDP and FUS can also result in a clinical presentation suggestive of FTLD 7, 122, 123 . Alphasynucleinopathies (MSA and LBD), TDP-43 proteinopathies and prion diseases have been clinically mistaken for PSP, CBD or FTLD 7, 31, 41, 42, 60 . This data emphasizes that no clinical syndrome is exclusive to tauopathies, as other pathophysiological mechanisms can lead to similar symptoms. It can therefore be very difficult to reach a correct clinical diagnosis without pathological confirmation.
CONCLUSION
The clinical presentations suggestive of PNFA, bv-FTD, PSP or CBD do not reliably predict the underlying pathology, as there is considerable overlap between these clinical and pathological syndromes. In particular, bv-FTD and PNFA, although not always associated with tau-positive inclusions, can be presentations of 4R-tauopathies like CBD and PSP. A PSP-like syndrome or CBS can be caused by either PSP, CBD or other tau-positive FTLD. It appears that similarities in clinical features arise from similarities in distribution of tau pathology, despite different types of tau aggregates. Furthermore, there are molecular and genetic evidences that support common pathophysiological roots for PSP and CBD.
Despite obvious overlapping features, there is not enough evidence to conclude that neurodegenerative tauopathies, or even 4R-tauopathies like PSP and CBD, are one single disease. Instead, we feel they should be viewed as part of the same disease spectrum. Future molecular research may reveal that all diseases with predominent tau deposition, even AD, arise from a single disease process which is influenced by genetic and environmental factors, leading to different clinical and pathological expressions. Hopefully, research focusing on pathophysiology of different tauopathies will lead to development of an anti-tau therapy, which could prove useful in treating patients with PSP, CBD, PNFA, FTLD and maybe even AD. 
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